135 related articles for article (PubMed ID: 32961011)
1. Diagnostic performance of the ClearLLab 10C B cell tube.
Espasa A; Torrents S; Morales-Indiano C; Rico LG; Bardina J; Ancochea A; Bistué-Rovira À; Linio R; Raya M; Vergara S; Juncà J; Grifols JR; Petriz J; Soria MG; Sorigue M
Cytometry B Clin Cytom; 2021 Jul; 100(4):519-530. PubMed ID: 32961011
[TBL] [Abstract][Full Text] [Related]
2. Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: basis for the design of specific four-color stainings to be used for minimal residual disease investigation.
Sánchez ML; Almeida J; Vidriales B; López-Berges MC; García-Marcos MA; Moro MJ; Corrales A; Calmuntia MJ; San Miguel JF; Orfao A
Leukemia; 2002 Aug; 16(8):1460-9. PubMed ID: 12145686
[TBL] [Abstract][Full Text] [Related]
3. Initial flow cytometric evaluation of the Clearllab lymphoid screen.
Hedley BD; Cheng G; Luider J; Kern W; Lozanski G; Chin-Yee I; Lowes LE; Keeney M; Careaga D; Magari R; Tejidor L
Cytometry B Clin Cytom; 2018 Sep; 94(5):707-713. PubMed ID: 29171939
[TBL] [Abstract][Full Text] [Related]
4. [Bone marrow immunophenotypes of 112 cases of lymphoid system malignant diseases].
Ling JY; Sun XF; Yan SL; He LR; Zhen ZJ; Xia Y
Ai Zheng; 2007 Apr; 26(4):418-22. PubMed ID: 17430665
[TBL] [Abstract][Full Text] [Related]
5. Utility of CD200 expression and CD20 antibody binding capacity in differentiating chronic lymphocytic leukemia from other chronic lymphoproliferative disorders.
Poongodi R; Varma N; Naseem S; Parveen B; Varma S
Indian J Pathol Microbiol; 2018; 61(1):50-57. PubMed ID: 29567884
[TBL] [Abstract][Full Text] [Related]
6. CD5-negative, CD10-negative small B-cell leukemia: variant of chronic lymphocytic leukemia or a distinct entity?
Sheikh SS; Kallakury BV; Al-Kuraya KA; Meck J; Hartmann DP; Bagg A
Am J Hematol; 2002 Dec; 71(4):306-10. PubMed ID: 12447961
[TBL] [Abstract][Full Text] [Related]
7. A multicenter study evaluation of the ClearLLab 10C panels.
Hedley BD; Cheng G; Keeney M; Kern W; Padurean A; Luider J; Chin-Yee I; Lowes LE; Rohrbach J; Ortega R; Smit A; Lo KW; Magari R; Tejidor L
Cytometry B Clin Cytom; 2021 Mar; 100(2):225-234. PubMed ID: 32667744
[TBL] [Abstract][Full Text] [Related]
8. Quantitative flow cytometry for the differential diagnosis of leukemic B-cell chronic lymphoproliferative disorders.
D'Arena G; Musto P; Cascavilla N; Dell'Olio M; Di Renzo N; Carotenuto M
Am J Hematol; 2000 Aug; 64(4):275-81. PubMed ID: 10911380
[TBL] [Abstract][Full Text] [Related]
9. CD5- B-cell lymphoproliferative disorders presenting in blood and bone marrow. A clinicopathologic study of 40 patients.
Shapiro JL; Miller ML; Pohlman B; Mascha E; Fishleder AJ
Am J Clin Pathol; 1999 Apr; 111(4):477-87. PubMed ID: 10191767
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of a 10color protocol as part of a 2tube screening panel for flow cytometric assessment of peripheral blood leukocytic subsets.
Gounari E; Tsavdaridou V; Ioakeimidou A; Haidich AB; Skoura L
Scand J Clin Lab Invest; 2019 Nov; 79(7):475-483. PubMed ID: 31497995
[TBL] [Abstract][Full Text] [Related]
11. CD200 Expression in Diagnostic and Prognostic Assessment of Mature B Cell Lymphophoproliferative Neoplasms.
El Din Fouad NB; Ibrahim NY; Abdel Aziz RS; Ibrahim SK
Asian Pac J Cancer Prev; 2018 Dec; 19(12):3383-3392. PubMed ID: 30583344
[TBL] [Abstract][Full Text] [Related]
12. Flow Cytometric Patterns of CD200 and CD1d Expression Distinguish CD10-Negative, CD5-Negative Mature B-Cell Lymphoproliferative Disorders.
Mason EF; Pozdnyakova O; Li B; Dudley G; Dorfman DM
Am J Clin Pathol; 2017 Jul; 148(1):33-41. PubMed ID: 28575142
[TBL] [Abstract][Full Text] [Related]
13. Measurement of lymphocyte aggregation by flow cytometry-physiological implications in chronic lymphocytic leukemia.
Dezorella N; Kay S; Baron S; Shapiro M; Porat Z; Deutsch V; Herishanu Y; Katz BZ
Cytometry B Clin Cytom; 2016 May; 90(3):257-66. PubMed ID: 26082241
[TBL] [Abstract][Full Text] [Related]
14. [Identification of splenic marginal zone lymphoma from B lymphoproliferative disorders by flow cytometry].
Hu Y; Chen Y; Wang LH; Chen X; Fang F; Liu SQ; Wu XQ; Zhu P
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Apr; 22(2):349-56. PubMed ID: 24763004
[TBL] [Abstract][Full Text] [Related]
15. Circulating levels of soluble CD23 reflect clinical and biological features of leukemic B-cell chronic lymphoproliferative disorders.
Vinante F; Vassanelli A; Zanotti R; Nadali G; Krampera M; Vincenzi C; Morosato L; Chilosi M; Pizzolo G
Int J Clin Lab Res; 1995; 25(4):189-94. PubMed ID: 8788546
[TBL] [Abstract][Full Text] [Related]
16. [Immunophenotyping of B chronic lymphoproliferative syndromes (CLL excluded): confrontation with the histology].
El Borgi W; Ben Salah N; Ben Lakhal F; Makni L; Gouider E; Hafsia R
Ann Biol Clin (Paris); 2013; 71(6):693-7. PubMed ID: 24342790
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of fixed-panel, multicolour ClearLLab 10C at an academic flow cytometry laboratory in Johannesburg, South Africa.
Glencross DK; Swart L; Pretorius M; Lawrie D
Afr J Lab Med; 2022; 11(1):1458. PubMed ID: 35937760
[TBL] [Abstract][Full Text] [Related]
18. [Relevance of cytological and immunophenotypical analysis for the diagnosis of B-cell chronic lymphocytic leukaemia].
Guillaume N; Alimardani G; Capiod JC; Claisse JF
Ann Biol Clin (Paris); 2002; 60(6):673-81. PubMed ID: 12446231
[TBL] [Abstract][Full Text] [Related]
19. Detection of CD5 in B-cell chronic lymphoproliferative diseases by flow cytometry: a strong expression in B-cell chronic lymphocytic leukemia.
Cavalcanti Júnior GB; Sales VS; Cavalcanti e Silva DG; Lopes MC; Paiva Ade S; da Fonseca HE; do Nascimento Júniors FF; Fernandes MZ
Acta Cir Bras; 2005; 20 Suppl 1():101-7. PubMed ID: 16186976
[TBL] [Abstract][Full Text] [Related]
20. Levels of expression of CD19 and CD20 in chronic B cell leukaemias.
Ginaldi L; De Martinis M; Matutes E; Farahat N; Morilla R; Catovsky D
J Clin Pathol; 1998 May; 51(5):364-9. PubMed ID: 9708202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
